Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 5,370 Shares

Posted by Trevor Kearing on Jan 24th, 2023

Natera, Inc. (NASDAQ:NTRA – Get Rating) CEO Steven Leonard Chapman sold 5,370 shares of Natera stock in a transaction on Monday, January 23rd. The shares were sold at an average price of $41.56, for a total value of $223,177.20. Following the completion of the transaction, the chief executive officer now owns 103,779 shares in the company, valued at $4,313,055.24. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

On Tuesday, January 3rd, Steven Leonard Chapman sold 8,212 shares of Natera stock. The shares were sold at an average price of $39.55, for a total value of $324,784.60.
On Wednesday, December 28th, Steven Leonard Chapman sold 2,605 shares of Natera stock. The shares were sold at an average price of $39.84, for a total value of $103,783.20.
On Friday, December 23rd, Steven Leonard Chapman sold 1,660 shares of Natera stock. The shares were sold at an average price of $42.30, for a total value of $70,218.00.
On Wednesday, December 7th, Steven Leonard Chapman sold 2,645 shares of Natera stock. The shares were sold at an average price of $38.31, for a total value of $101,329.95.

Natera Stock Performance

NTRA traded down $0.29 on Tuesday, reaching $42.94. 1,481,794 shares of the stock were exchanged, compared to its average volume of 1,579,353. The firm has a market capitalization of $4.19 billion, a PE ratio of -7.56 and a beta of 1.28. The company’s 50-day moving average price is $39.55 and its 200 day moving average price is $44.06. The company has a debt-to-equity ratio of 0.78, a current ratio of 3.10 and a quick ratio of 2.95. Natera, Inc. has a fifty-two week low of $26.10 and a fifty-two week high of $74.82.

Natera (NASDAQ:NTRA – Get Rating) last issued its quarterly earnings data on Tuesday, November 8th. The medical research company reported ($1.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.42) by $0.17. The business had revenue of $210.64 million during the quarter, compared to analysts’ expectations of $208.31 million. Natera had a negative return on equity of 109.07% and a negative net margin of 70.34%. As a group, sell-side analysts forecast that Natera, Inc. will post -5.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on NTRA. Stephens dropped their target price on Natera to $67.00 in a research note on Wednesday, November 16th. Piper Sandler restated an “overweight” rating and set a $70.00 target price on shares of Natera in a research note on Tuesday, January 17th. StockNews.com began coverage on Natera in a research note on Wednesday, October 12th. They set a “sell” rating on the stock. Robert W. Baird dropped their target price on Natera from $72.00 to $65.00 in a research note on Wednesday, November 9th. Finally, Raymond James upgraded Natera from a “market perform” rating to an “outperform” rating and set a $58.00 target price on the stock in a research note on Wednesday, January 18th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $81.67.

Hedge Funds Weigh In On Natera

Several institutional investors and hedge funds have recently modified their holdings of NTRA. Bank of New York Mellon Corp lifted its holdings in shares of Natera by 6.7% in the 1st quarter. Bank of New York Mellon Corp now owns 820,974 shares of the medical research company’s stock valued at $33,399,000 after buying an additional 51,791 shares during the period. US Bancorp DE raised its holdings in Natera by 20.0% in the 1st quarter. US Bancorp DE now owns 16,180 shares of the medical research company’s stock worth $658,000 after purchasing an additional 2,698 shares during the period. PNC Financial Services Group Inc. raised its holdings in Natera by 215.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,049 shares of the medical research company’s stock worth $83,000 after purchasing an additional 1,399 shares during the period. Bank of Montreal Can raised its holdings in Natera by 80.6% in the 1st quarter. Bank of Montreal Can now owns 130,062 shares of the medical research company’s stock worth $5,390,000 after purchasing an additional 58,049 shares during the period. Finally, MetLife Investment Management LLC acquired a new position in Natera in the 1st quarter worth about $209,000. Institutional investors and hedge funds own 93.81% of the company’s stock.

Natera Company Profile

(Get Rating)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.